A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2022-04-25
AEs
4
Serious
1
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-05-16 (study day 12); relationship: N
severe
serious
assessed
Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-05-18 (study day 14); relationship: not assessed; serious criteria: hospitalization
mild
assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-05-19 (study day 15); relationship: Y
moderate
assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-06-01 (study day 28); relationship: not assessed
Data queries
No data queries.